Amgen To Additionally Invest $421 Mln In China's BeiGene

安进将在中国投资4.21亿美元

2020-07-13 14:05:21 RTTNews

本文共279个字,阅读需1分钟

Amgen said it will additionally invest about $421 million in Chinese biotech company BeiGene's registered direct offering of ordinary shares. The investment maintains Amgen's current pro rata ownership of BeiGene at about 20.3%. Amgen said the additional investment reflects its confidence in the progress the companies are making in their ongoing oncology collaboration in China. Earlier today, Beigene said it plans to raise $2.08 billion in a direct offering of 145.84 million shares. The shares will be priced at $14.23 per share or $185 per American Depositary Share. The offering is expected to close on or around July 15. For comments and feedback contact: editorial@rttnews.com Business News
安进(Amgen)表示,将另外投资约4.21亿美元,投资于中国生物科技公司贝能( BeiGene )的注册直接发行普通股。本次投资保持安进(Amgen)目前按比例拥有北基因约20.3%的股权。 安进(Amgen)表示,这笔额外投资反映出它对两家公司在中国正在进行的肿瘤合作取得的进展充满信心。 今天早些时候,贝金表示,计划通过直接发行1.4584亿股股票募集20.8亿美元。这些股票的定价为每股14.23美元,或每股美国存托股票185美元。此次发行预计将于7月15日或前后结束。 有关意见和反馈,请联系: edition @ rttnews.com 商业新闻

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文